Under active development. Data is being added and corrected on an hourly basis.

← Back to Peptides
Semaglutide structure

Semaglutide

Metabolic
Approved Research
100%
Low Risk
1/5

Also Known As

Ozempic · Wegovy · Rybelsus

Overview

Semaglutide is a long-acting GLP-1 analog. FDA approved for diabetes (Ozempic) and weight management (Wegovy). Works by mimicking incretin hormones.

Mechanism of Action

Activates GLP-1 receptors, increasing insulin secretion, reducing glucagon, slowing gastric emptying, and reducing appetite.

Quick Reference

Common Dose 0.25mg-2.4mg
Frequency Once weekly
Half-Life ~7 days
Storage Refrigerate.

Notes

Titrate slowly to minimize GI side effects. Do not use if history of MTC or MEN2.